Test Prenatal No Invasivo
El test prenatal no invasivo en sangre materna es el test de cribado prenatal más fiable y seguro disponible actualmente. Permite detectar alteraciones en los 24 cromosomas


Non-Invasive Prenatal Test

During pregnancy, small amounts of fetal cell-free DNA that pass through the placenta can be detected in the mother’s blood. SafeBaby® non-invasive prenatal test screens this fetal DNA to identify the presence of alterations in the chromosomes of the baby.

SafeBaby® is the most reliable and safe prenatal screening option currently available, with no associated risks for either the mother or the fetus. From a single tube of mother´s blood, drawn as early as 10 weeks in the pregnancy, this test allows determining if the future baby presents any chromosome alteration.


SafeBaby® Non-invasive prenatal testing in the mother’s blood allows the detection of all 24 fetal chromosome alterations.

Mother´s blood draw
(10ml) at 10 weeks +

Keep the blood sample
at room temperature
until shipping.

Ship at room

Cell-free fetal
DNA analysis.

Results in 7
working days.


SafeBaby® Non-invasive prenatal testing in the mother’s blood allows the detection of all 24 fetal chromosome alterations.

For the peace of mind of expectant mothers.


Add quality and confidence to your assisted reproduction treatment: go one step further and include the SafeBaby® test in your process. 


Tell your gynaecologist, he or she will show you how SafeBaby® can make a difference.


Your doctor will find the right option for you.


Your doctor will take care of everything so that we can continue to look after you as you deserve in your journey towards motherhood.

What is SafeBaby, the non-invasive prenatal maternal blood test?

SafeBaby® Non-Invasive Prenatal Test (NIPT) in mother’s blood is a new prenatal screen test that allows to identify the presence of fetal chromosome anomalies. This test represents a great advance in prenatal screening.

By carrying out a simple blood test from week 10 of pregnancy, remnants of fetal genetic material that pass through the placenta can be detected in the mother’s blood. From the study of this fetal material, it is possible to foresee the possibility that the future baby suffers from any chromosome alteration.

What is SafeBaby, the non-invasive prenatal maternal blood test?

Non-invasive prenatal testing results are the most precise prenatal screening tests results currently available, such as the traditional combined screening of the first trimester (3).

In general, the probability of obtaining a false positive or false negative result is lower than in other tests (1-3).

This test detects alterations in all human complement chromosomes (main trisomies: Down’s, Patau’s and Edwards’ syndrome),, with a sensitivity and specificity higher than 98% and 99% respectively.

This test is also useful to detect aneuploidies in the sex chromosomes with sensitivity and specificity greater than 95% and 99% respectively (1-3).

It also detects gains or losses of chromosome fragments of + 7mb, with high specificity and sensitivity the presence of microdeletions associated to the following syndromes: Prader-Willi/Angelman 1p36 deletion, Cri du Chat, Wolf-Hirschhorn, Jacbosen, Langer Giedion, DiGeorge II, Phelan-McDermid and 16p11.2-p12.2 deletion.

Benefits and added value 

IGLS uses SafeBaby® non-invasive prenatal test to determine, by means of massive sequencing of the entire genome, the presence of fetal aneuploidies in all 24 chromosomes and CNVS (fetal chromosome fragment gains and losses).

This test has significantly higher detection rates than traditional methods (1-4) and has shown excellent detection rates and very low false positive rates compared to other non-invasive prenatal diagnosis methods (5).

Who can benefit from the TPNI?

Medical societies have recommended SafeBaby® as an option for all pregnant women regardless of age or risk (1-2).

This screening test is aimed at patients with gestation of 10 weeks or more with single or twin pregnancies.

It is particularly beneficial for woman of advanced maternal age (≥ 35 years), who have had an abnormal result in the combined screening of the first trimester, an abnormal ultrasound or a medical history that suggests an increased risk of a pregnancy with chromosome aneuploidies.

How is the SafeBaby® process carried out?

The non invasive prenatal test requires 10 ml blood sample. Once drawn, it must be sent at room temperature to a laboratory where an extraction of both maternal and fetal genetic material will be performed.

This material will be then analyzed using state-of-the-art next generation sequencing technology.

From the analysis of the sequencing results, the amount of fetal and maternal DNA present for each of the chromosomes analyzed will be determined.

And thus the probability that the fetus suffers from aneuploidy or microdeletions can be elucidated.

Our results reports are available in 7 days after sample reception.

1. Practice Bulletin No. 163. Obstet Gynecol. 2016; 127(5): 979-981.
2. Gregg AR et al. Genet Med. 2016; 18(10): 1056-1065.
3. Bianchi DW et al. 2014; 370(9): 799-808.
4. Norton ME et al. N Engl J Med. 2015; 372(17): 1589-1597.
5. Gil MM et al. Ultrasound Obstet Gynecol. 2015; 45(3): 249-266.